7 completed, 7 unknown, 5 recruiting, 3 terminated. 25 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 25 | Completed 7, Unknown 7, Recruiting 5, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx) - Heart Failure With Reduced Ejection Fraction | Phase 4 | Recruiting | University of Michigan | 100 | 2026-12-01 | 2026-10-15 |
| STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy - Heart Failure With Reduced Ejection Fraction, Heart Failure | Phase 4 | Recruiting | Kyungsub Song | 80 | 2026-08-12 | 2026-09-02 |
| Efficacy and Safety of Lactoferrin in Heart Failure Patients oral Iron, Lactoferrin, lactoferrin and oral iron - Heart Failure With Reduced Ejection Fraction | Phase 4 | Not yet recruiting | Cairo University | 114 | 2024-07-01 | 2024-05-24 |
| SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF Dapagliflozin tablet, Hypertonic Saline Solution, 1 Ml, Furosemide Injection - Heart Failure Acute, Diabetes Type 2 | Phase 4 | Unknown | University of Palermo | 544 | 2024-06-01 | 2024-06-06 |
| Colchicine in Acutely Decompensated HFREF Colchicine 0.6 mg, Control/Placebo group - Heart Failure, Decompensated Heart Failure | Phase 4 | Recruiting | University of Virginia | 30 | 2024-06-01 | 2024-05-08 |
| Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease Empagliflozin 25 MG, Placebo - Heart Failure With Reduced Ejection Fraction, End Stage Renal Disease on Dialysis | Phase 4 | Recruiting | National Taiwan University Hospital | 95 | 2024-03-13 | 2026-10-28 |
| Determination of Drug Levels for Pharmacotherapy of Heart Failure Nebivolol, Valsartan and Sacubitril, Carvedilol - Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction | Phase 4 | Unknown | University Hospital Ostrava | 100 | 2024-03-01 | 2024-01-18 |
| Initiation of ARNi and SGLT2i in Patients With HFrEF Sacubitril-valsartan, SGLT2 inhibitor - Heart Failure With Reduced Ejection Fraction | Phase 4 | Completed | Universidade do Porto | 62 | 2023-08-04 | 2025-11-19 |
| The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF) Ferric derisomaltose, Placebo - Heart Failure With Reduced Ejection Fraction, Iron Deficiency | Phase 4 | Recruiting | China-Japan Friendship Hospital | 146 | 2023-08-01 | 2026-11-06 |
| SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency SGLT-2 inhibitor - Heart Failure With Reduced Ejection Fraction, Renal Insufficiency, Chronic | Phase 4 | Terminated | Peking University People's Hospital | 11 | 2023-03-09 | 2024-04-30 |
| Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B) CardioMEMS HF System, Standard heart failure medical therapy - Advanced Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 4 | Unknown | Finn Gustafsson | 60 | 2023-03-02 | 2023-03-20 |
| ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF Ertugliflozin, Placebo - Heart Failure With Reduced Ejection Fraction, Congestion | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 28 | 2023-02-02 | 2026-05-11 |
| Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction Empagliflozin 10 MG - Heart Failure With Reduced Ejection Fraction | Phase 4 | Unknown | Alexandria University | 60 | 2022-12-15 | 2023-03-21 |
| Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction GDMT - Heart Failure With Reduced Ejection Fraction | Phase 4 | Active not recruiting | Göteborg University | 60 | 2022-10-22 | 2025-04-15 |
| HF Patients With LVADs Being Treated With SGLT2i SGLT2i, No SGLT2i - Heart Failure With Reduced Ejection Fraction | Phase 4 | Completed | University of Chicago | 32 | 2022-09-08 | 2026-06-03 |
| Levosimendan In Ambulatory Heart Failure Patients Levosimendan, Placebo - Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV | Phase 4 | Terminated | Medical University of Bialystok | 70 | 2021-12-15 | 2025-05-09 |
| Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus Empagliflozin 10 mg, Placebo - Heart Failure With Reduced Ejection Fraction | Phase 4 | Completed | Ashraf Wasfy Beshay Aziz | 74 | 2021-07-26 | 2024-10-09 |
| Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone Sodium zirconium cyclosilicate, Placebo, Spironolactone - Hyperkalaemia, Heart Failure With Reduced Ejection Fraction | Phase 4 | Completed | AstraZeneca | 366 | 2021-03-08 | 2025-07-09 |
| The Effects of SGLTi on Diabetic Cardiomyopathy Dapagliflozin - Type2 Diabetes, Heart Failure With Reduced Ejection Fraction | Phase 4 | Unknown | The University of Hong Kong | 30 | 2020-04-09 | 2021-08-03 |
| Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients Atorvastatin Oral Tablet, Rosuvastatin Oral Tablet - Heart Failure With Reduced Ejection Fraction | Phase 4 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 80 | 2019-10-16 | 2021-10-19 |
Showing 20 of 25. Sign in to see all of them.
Heart Failure (6) · Cardiovascular Diseases (2) · Iron Deficiencies (2) · Diabetes Mellitus, Type 2 (1) · Genetic Risk Score (1) · Heart Failure, Systolic (1) · Heart Valve Diseases (1) · Hyperkalemia (1) · Kidney Failure, Chronic (1) · Renal Insufficiency, Chronic (1) · Ventricular Dysfunction, Left (1)
Heart Diseases (7) · Cardiovascular Diseases (6) · Metabolic Diseases (4) · Nutritional and Metabolic Diseases (4) · Disease Attributes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Iron Metabolism Disorders (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Renal Insufficiency (2) · Urogenital Diseases (2)
sacubitril and valsartan sodium hydrate drug combination (4) · Sodium-Glucose Transporter 2 Inhibitors (3) · empagliflozin (3) · Iron (2) · Metoprolol (2) · Spironolactone (2) · dapagliflozin (2) · Atorvastatin (1) · Bisoprolol (1) · Carvedilol (1) · Chlorothiazide (1) · Colchicine (1) · Diastole (1) · Echocardiography (1) · Enalapril (1)
University of Virginia (2) · Alexandria University (1) · Ashraf Wasfy Beshay Aziz (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · Cairo University (1) · China-Japan Friendship Hospital (1) · Finn Gustafsson (1) · Fundación para la Investigación del Hospital Clínico de Valencia (1) · Göteborg University (1) · Icahn School of Medicine at Mount Sinai (1) · Kyungsub Song (1) · Medical University of Bialystok (1) · National Taiwan University Hospital (1) · Novartis Pharmaceuticals (1)
United States (6) · Czechia (3) · Poland (3) · Spain (3) · Canada (2) · China (2) · Egypt (2) · Portugal (2) · South Korea (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Belgium (1) · Brazil (1) · Denmark (1)
Antonio Abbate, MD (1) · Ashish K Kakkar (1) · Carlos G Santos-Gallego, MD (1) · Chih-Cheng Wu, MD. PhD (1) · Donna Shu-Han Lin, MD (1) · Finn Gustafsson, MD, professor, PhD, DMSci (1) · Giuseppe Miceli, PhD (1) · Hesham B Mahmoud, Professor of Cardiology (1) · Hyung Gon Je, Professor (1) · Jacek Kubica, Prof. MD (1) · Jadwiga Nessler, Prof. MD (1)
PMID 15963399, PMID 20607462, PMID 21440872, PMID 21885793, PMID 22980301, PMID 26240596, PMID 29239515, PMID 29433525, PMID 31134724, PMID 31820537, PMID 32139695, PMID 32709292, PMID 32800508, PMID 32970396, PMID 34447992, PMID 35066737, PMID 35241246, PMID 35604416, PMID 36607775, PMID 37391470, PMID 37676213, PMID 37678704, PMID 38878009, PMID 39566872, PMID 40855136
2015 (1), 2018 (1), R01HL178410 (1)